Dose escalation of lenalidomide in relapsed or refractory acute leukemias

William Blum, Rebecca B. Klisovic, Heiko Becker, Xiaoxia Yang, Darlene M. Rozewski, Mitch A. Phelps, Ramiro Garzon, Alison Walker, Jason C. Chandler, Susan P. Whitman, John Curfman, Shujun Liu, Larry Schaaf, Jon Mickle, Cheryl Kefauver, Steven M. Devine, Michael R. Grever, Guido Marcucci, John C. Byrd

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

Purpose: Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia. Patients and Methods: Thirty-one adults with acute myeloid leukemia (AML) and four adults with acute lymphoblastic leukemia (ALL) were enrolled. Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide pharmacokinetic and preliminary efficacy data. Results: Patients had a median age of 63 years (range, 22 to 79 years) and a median of two prior therapies (range, one to four therapies). The DLT was fatigue; 50 mg/d was the MTD. Infectious complications were frequent. Plasma lenalidomide concentration increased proportionally with dose. In AML, five (16%) of 31 patients achieved complete remission (CR); three of three patients with cytogenetic abnormalities achieved cytogenetic CR (none with deletion 5q). Response duration ranged from 5.6 to 14 months. All responses occurred in AML with low presenting WBC count. No patient with ALL responded. Two of four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after development of cutaneous graft-versus-host disease, without donor leukocyte infusion. Conclusion: Lenalidomide was safely escalated to 50 mg daily for 21 days, every 4 weeks, and was active with relatively low toxicity in patients with relapsed/refractory AML. Remissions achieved after transplantation suggest a possible immunomodulatory effect of lenalidomide, and results provide enthusiasm for further studies in AML, either alone or in combination with conventional agents or other immunotherapies.

Original languageEnglish (US)
Pages (from-to)4919-4925
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number33
DOIs
StatePublished - Nov 20 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'Dose escalation of lenalidomide in relapsed or refractory acute leukemias'. Together they form a unique fingerprint.

Cite this